Phospholipase A 2 is an important enzyme involved in the production of prostaglandins and their related compounds causing inflammatory disorders. Among the several peptides tested, the peptide Phe-Leu-Ser-Tyr-Lys (FLSYK) showed the highest inhibition. The dissociation constant (K d ) for this peptide was calculated to be 3.57 ؎ 0.05 ؋ 10 ؊9 M. In order to further improve the degree of inhibition of phospholipase A 2 , a complex between Russells viper snake venom phospholipase A 2 and a peptide inhibitor FLSYK was crystallized, and its structure was determined by crystallographic methods and refined to an R-factor of 0.205 at 1.8 Å resolution. Phospolipase A 2 (EC 3.1.1.4, PLA 2 ) 1 enzyme specifically cleaves the sn-2 acyl ester bond of phospholipids (1). These enzymes were first described as components of snake venoms and were later identified in mammals. PLA 2 s of mammalian origin were found in the pancreas (2), blood platelets, macrophages, and neutrophils (3, 4). These are also found in fluids derived from patients with inflammatory conditions (5, 6) and are induced in several cell types in response to inflammatory stimuli (4). It is understood that the concentrations of PLA 2 enzymes in serum and tissues correlate with the disease severity in several immune-mediated inflammatory pathologies in humans. These are also associated with the onset of rheumatoid arthritis (7, 8) and septic shock (5, 9). Therefore, it is of great interest to develop specific inhibitors for each of these enzymes. Several crystal structures of the tetrahedral mimic inhibitors with an sn-2-phosphate, substituent, L-1-(O-octyl-2-(heptyl phosphonyl)-sn-glycero-3-phosphoethanolamine, complexed with secreted PLA 2 from Chinese cobra venom (10), bee venom (11), and inflammatory exudates (12) have been reported. Also the crystal structure of an sn-2-acyl-amino analogue of phospholipids complexed with the engineered (without the residues of the surface 62-66) porcine PLA 2 (13) has been determined. The crystal structures of the complexes of bovine pancreatic PLA 2 with an inhibitor n-dodecyl-phosphorylcholine (14) and human synovial PLA 2 with an acyl amino analogue of phospholipids (15) are also of some interest. Recently, a series of indole inhibitors of human secretory PLA 2 were developed (16). Further, there is an example of a natural inhibition (17) where specific interactions from one molecule of a heterodimer acts as a natural inhibitor for the other. The synthetic peptides derived from the primary sequence of the PLA 2 itself were also studied as specific inhibitors (18,19). The kinetic studies (18, 19) support their high inhibitory potencies. These peptide inhibitors were stable against acyl esterase as well as phospholipase A 1 , C, and D. Therefore, they were suited for in vivo studies where phospholipids may be more readily metabolized. As part of the program on structure-based rational design of specific potent inhibitors using a model snake venom phospholipase A 2 , we have synthesized a number of peptides (20). One of these ...